Advanced Biomed Inc. (NASDAQ:ADVB – Get Free Report) saw a significant increase in short interest during the month of September. As of September 30th, there was short interest totaling 18,897 shares, an increase of 91.9% from the September 15th total of 9,845 shares. Based on an average daily trading volume, of 22,487 shares, the short-interest ratio is currently 0.8 days. Currently, 1.6% of the shares of the company are short sold.
Wall Street Analyst Weigh In
Several research analysts have recently commented on ADVB shares. Wall Street Zen upgraded Advanced Biomed to a “hold” rating in a research note on Saturday, August 22nd. Weiss Ratings cut Advanced Biomed from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, October 8th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock has an average rating of “Sell”.
View Our Latest Stock Analysis on Advanced Biomed
Advanced Biomed Stock Down 5.1%
Shares of ADVB stock opened at $4.88 on Friday. The firm has a 50 day moving average price of $7.60 and a two-hundred day moving average price of $6.47. The company has a market capitalization of $8.05 million, a PE ratio of 1.02 and a beta of 0.01. Advanced Biomed has a 12-month low of $3.61 and a 12-month high of $24.23.
Advanced Biomed (NASDAQ:ADVB – Get Free Report) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $0.44 earnings per share (EPS) for the quarter.
About Advanced Biomed
Advanced Biomed Inc is a clinical-stage biopharmaceutical company focused on developing radiopharmaceutical products for the diagnosis and treatment of cancer.
The company’s research is centered on radioligand therapies, which use targeting molecules to deliver radioactive substances directly to cancer cells. Its development programs include products designed to target prostate-specific membrane antigen (PSMA), an established target in prostate cancer.
Advanced Biomed’s programs remain subject to clinical development and regulatory review.
See Also
- Five stocks we like better than Advanced Biomed
- Expecting a Market Correction? This Mega-Cap ETF Deserves a Spot on Your Watchlist
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
Receive News & Ratings for Advanced Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
